$BLGO BioLargo Subsidiary Clyra Medical Accelerates Toward Near-Term Product Launches and Global Expansion
https://www.accessnewswire.com/newsroom/en/ch...ba-1086012
Initial Commercialization Targeting $732 Million Wound Care Market is Expected in Late 2025 or Early 2026
WESTMINSTER, CALIFORNIA / ACCESS Newswire / October 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that creates and commercializes sustainable technologies, today announced that its subsidiary Clyra Medical Technologies has achieved noteworthy progress across product development, commercialization, and clinical programs, advancing toward multiple near-term market launches and international expansion.
ViaCLYR: Market Launch on Track
Clyra's ViaCLYR, an advanced wound irrigation and antimicrobial solution, remains on schedule for commercial launch in late 2025 or early 2026 through multiple established distributors with domestic and international reach. The company is also expanding collaborations with clinicians to conduct targeted evaluations supporting applications in antimicrobial, wound care, and surgical markets.
Under a distribution agreement signed earlier this year, Clyra is advancing into the Europe-Middle East-Africa (EMEA) region through partnerships with international distributors. Initial product sales in the region are anticipated to begin in late 2025 or early 2026. Initial sales will be limited to those nation-states that recognize the existing FDA clearances, and others will require a CE Mark (an EU certification process to ensure health, safety and environmental protections standards are met), which is underway.
Global Wound Irrigation Solution Market Size
According to Fact.MR an international provider of data-driven market intelligence solutions across several industries, "The global wound irrigation solution market is evaluated at a size of US$ 732 million in 2024 and has been forecasted to expand at a CAGR of 3.4% to reach US$ 1.02 billion by the end of 2034." The growing number of chronic diseases like diabetes and vascular conditions leads to a higher demand for wound care solutions. Hospitals and clinics are increasingly adopting wound irrigation as a protocol to prevent surgical site infections.
Surgical Market Expansion
Following the execution of another distribution agreement in Q2 2025, Clyra has achieved several key milestones toward the commercial launch of its surgical products. These milestones include completion of package and label design, as well as finalized product claims. The next steps, already in process, will focus on product stability testing, packaging validation, and process validation. Upon completion, the full package will undergo standard FDA submission and review.
Our major distribution partner has been engaged throughout every stage of development in preparation for launch. Together, we anticipate that Clyra's surgical application products will be made available at more than 6,000 hospitals, 6,300 ambulatory surgery centers, and 2,200 specialty wound care clinics across the United States.
Market Diversification and Innovation
Building on its proven platform technology, Clyra is developing new product delivery systems and expanded applications for infection prevention and wound management diversifying its offerings across multiple medical markets that management believes will expand the total addressable markets for Clyra products as they are commercialized.
Capital and Growth
Over the past 12 months Clyra has secured over $7.5 million in capital to support capital investments, product rollouts, manufacturing readiness, and market expansion. The company continues to evaluate strategic funding opportunities to sustain its growth trajectory and maximize shareholder value.
Executive Commentary
"We are excited to bring these innovations to market and see our years of development translate into real clinical impact," said Steve Harrison, CEO of Clyra Medical. "Our expanding team remains focused on delivering world-class antimicrobial solutions that improve patient care and safety. For more information, visit www.ClyraMedical.com."
"Clyra represents a major technical advancement in infection control and wound care," said Dennis P. Calvert, CEO of BioLargo and Chairman of Clyra Medical Technologies. "We believe its products will set a new standard in antimicrobial performance and deliver exceptional value to patients, clinicians, and shareholders as adoption expands globally. Clyra exemplifies BioLargo's mission to develop high-impact technologies that create meaningful value for humanity and our investors."
https://www.accessnewswire.com/newsroom/en/ch...ba-1086012
Initial Commercialization Targeting $732 Million Wound Care Market is Expected in Late 2025 or Early 2026
WESTMINSTER, CALIFORNIA / ACCESS Newswire / October 13, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that creates and commercializes sustainable technologies, today announced that its subsidiary Clyra Medical Technologies has achieved noteworthy progress across product development, commercialization, and clinical programs, advancing toward multiple near-term market launches and international expansion.
ViaCLYR: Market Launch on Track
Clyra's ViaCLYR, an advanced wound irrigation and antimicrobial solution, remains on schedule for commercial launch in late 2025 or early 2026 through multiple established distributors with domestic and international reach. The company is also expanding collaborations with clinicians to conduct targeted evaluations supporting applications in antimicrobial, wound care, and surgical markets.
Under a distribution agreement signed earlier this year, Clyra is advancing into the Europe-Middle East-Africa (EMEA) region through partnerships with international distributors. Initial product sales in the region are anticipated to begin in late 2025 or early 2026. Initial sales will be limited to those nation-states that recognize the existing FDA clearances, and others will require a CE Mark (an EU certification process to ensure health, safety and environmental protections standards are met), which is underway.
Global Wound Irrigation Solution Market Size
According to Fact.MR an international provider of data-driven market intelligence solutions across several industries, "The global wound irrigation solution market is evaluated at a size of US$ 732 million in 2024 and has been forecasted to expand at a CAGR of 3.4% to reach US$ 1.02 billion by the end of 2034." The growing number of chronic diseases like diabetes and vascular conditions leads to a higher demand for wound care solutions. Hospitals and clinics are increasingly adopting wound irrigation as a protocol to prevent surgical site infections.
Surgical Market Expansion
Following the execution of another distribution agreement in Q2 2025, Clyra has achieved several key milestones toward the commercial launch of its surgical products. These milestones include completion of package and label design, as well as finalized product claims. The next steps, already in process, will focus on product stability testing, packaging validation, and process validation. Upon completion, the full package will undergo standard FDA submission and review.
Our major distribution partner has been engaged throughout every stage of development in preparation for launch. Together, we anticipate that Clyra's surgical application products will be made available at more than 6,000 hospitals, 6,300 ambulatory surgery centers, and 2,200 specialty wound care clinics across the United States.
Market Diversification and Innovation
Building on its proven platform technology, Clyra is developing new product delivery systems and expanded applications for infection prevention and wound management diversifying its offerings across multiple medical markets that management believes will expand the total addressable markets for Clyra products as they are commercialized.
Capital and Growth
Over the past 12 months Clyra has secured over $7.5 million in capital to support capital investments, product rollouts, manufacturing readiness, and market expansion. The company continues to evaluate strategic funding opportunities to sustain its growth trajectory and maximize shareholder value.
Executive Commentary
"We are excited to bring these innovations to market and see our years of development translate into real clinical impact," said Steve Harrison, CEO of Clyra Medical. "Our expanding team remains focused on delivering world-class antimicrobial solutions that improve patient care and safety. For more information, visit www.ClyraMedical.com."
"Clyra represents a major technical advancement in infection control and wound care," said Dennis P. Calvert, CEO of BioLargo and Chairman of Clyra Medical Technologies. "We believe its products will set a new standard in antimicrobial performance and deliver exceptional value to patients, clinicians, and shareholders as adoption expands globally. Clyra exemplifies BioLargo's mission to develop high-impact technologies that create meaningful value for humanity and our investors."
